SM-06-09 是一种高效、高选择性、具有口服活性的四唑酮类 HDAC6 抑制剂,IC50 值为 0.49 nM,可促进肿瘤相关巨噬细胞(Tumor-Associated Macrophages,TAMs)向抗肿瘤 M1 样表型极化,并增强巨噬细胞吞噬作用、抗原呈递及 T 细胞活化,从而重塑肿瘤免疫微环境,在黑色素瘤模型中表现出显著抗肿瘤活性,并增强抗 PD-1 免疫检查点阻断的活性。
SM-06-09
产品编号: MS-Y00653 分子式: C16H13N7O4 分子量: 367.32
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SM-06-09 是一种高效、高选择性、具有口服活性的四唑酮类 HDAC6 抑制剂,IC50 值为 0.49 nM,可促进肿瘤相关巨噬细胞(Tumor-Associated Macrophages,TAMs)向抗肿瘤 M1 样表型极化,并增强巨噬细胞吞噬作用、抗原呈递及 T 细胞活化,从而重塑肿瘤免疫微环境,在黑色素瘤模型中表现出显著抗肿瘤活性,并增强抗 PD-1 免疫检查点阻断的活性。

生物实验数据

生物活性 SM-06-09 is a potent, highly selective, orally active tetrazolone-based HDAC6 inhibitor with an IC50 value of 0.49 nM that promotes the polarization of tumor-associated macrophages (TAMs) toward an antitumor M1-like phenotype and enhances macrophage phagocytosis, antigen presentation, and T cell activation, thereby remodeling the tumor immune microenvironment, exhibiting significant antitumor activity in melanoma models, and enhancing the activity of anti-PD-1 immune checkpoint blockade.
IC50 & Target

HDAC6

0.49 nM (IC50)

HDAC10

16.9 nM (IC50)

HDAC2

173 nM (IC50)

HDAC3

258 nM (IC50)

HDAC1

338 nM (IC50)

HDAC8

453 nM (IC50)

HDAC7

4443 nM (IC50)

HDAC5

7602 nM (IC50)

HDAC4

12415 nM (IC50)

HDAC9

26035 nM (IC50)

HDAC11

1891 nM (IC50)

HDAC6

9.31 (pIC50)

体外研究
(In Vitro)

SM-06-09 (Compound 3m) 对 HDAC6 的 IC50 值为 0.49 nM,对 HDAC10 (16.9 nM)、HDAC2 (173 nM)、HDAC3 (258 nM)、HDAC1 (338 nM) 和 HDAC8 (453 nM) 具有良好选择性。
SM-06-09 (0.15-10 μM) 在 RAW264.7 巨噬细胞中剂量依赖性抑制总 HDAC 活性,在 10 μM 时抑制率约 85%。
SM-06-09 (0.5-10 μM;24小时) 在 RAW264.7 巨噬细胞中可升高乙酰化 α- 微管蛋白水平,证实其细胞内 HDAC6 抑制作用。
SM-06-09 (0.15-20 μM;24小时) 在 RAW264.7 细胞中几乎无明显细胞毒性,在最高浓度下细胞生长抑制率 <10%。
SM-06-09 (5 μM;极化后 16小时) 在骨髓来源巨噬细胞 (BMDMs) 中促进 M1 型极化,上调 Tnf 和 Nos2 并下调 Arg1 和 Fizz1,同时 SM-06-09 (5 μM) 降低 Arg1 蛋白表达并维持 iNOS 水平。
SM-06-09 (5 μM) 在 M1 和 M2 极化的骨髓来源巨噬细胞 (BMDMs) 中诱导转录组重编程,下调 Arg1 和 Retnla 等 M2 相关基因表达,同时上调 Cxcl3、Cxcl5 和 C3 等促炎基因表达。SM-06-09 促进与抗原呈递、T 细胞活化及 TNF/IFN 炎症信号相关通路的富集,并抑制与细胞外基质组织和间充质分化相关通路。
SM-06-09 (5 μM) 在 BMDMs 中诱导持续性 HDAC6 抑制作用,单次处理后乙酰化 α-微管蛋白水平可持续升高至 120 小时,同时 SM-06-09 增强 SM1 黑色素瘤细胞吞噬作用,抑制 M2 巨噬细胞迁移 (2.5 μM;24 小时),并促进抗原呈递、CD8+ T 细胞活化与增殖。

Real Time qPCR

Cell Line: Mouse bone marrow-derived macrophages (BMDMs)
Concentration: 0.5, 1, 2.5, 5, and 10 μM
Incubation Time: 16 h after polarization
Result: Increased expression of M1-associated genes Tnf and Nos2 and decreased expression of M2-associated genes Arg1 and Fizz1.

Cell Viability Assay

Cell Line: RAW264.7 macrophages
Concentration: 10, 5, 2.5, 1.25, 0.625, 0.312 and 0.156 μM
Incubation Time: 24 h
Result: Displayed minimal cytotoxicity (<10%) throughout the tested concentration range.

Cell Migration Assay

Cell Line: UBC-GFP mouse BMDMs and SM1 melanoma cells
Concentration: 2.5 μM pretreatment
Incubation Time: 24 h
Result: Significantly reduced migration of M2-like macrophages toward SM1 melanoma cells.

Cell Proliferation Assay

Cell Line: Murine splenic T cells cocultured with BMDMs (M1-polarized)
Concentration: Effective concentrations consistent with prior macrophage treatments (primarily 5 μM)
Incubation Time: 72 h
Result: Significantly increased CD8+ T-cell proliferation following coculture with SM-06-09-treated M1 macrophages.

Western Blot Analysis

Cell Line: Mouse bone marrow-derived macrophages (BMDMs)
Concentration: 0.5, 1, 2.5, 5, and 10 μM
Incubation Time: 24 h after polarization
Result: Reduced Arg1 protein expression and increased or maintained iNOS protein expression.

Western Blot Analysis

Cell Line: Mouse bone marrow-derived macrophages (BMDMs)
Concentration: 0.5, 1, 2.5, 5, and 10 μM
Incubation Time: Up to 120 h
Result: Maintained elevated acetylated α-tubulin levels for up to 120 h following a single treatment.

Western Blot Analysis

Cell Line: RAW264.7 macrophages
Concentration: 0.5, 1, 2.5, 5, and 10 μM
Incubation Time: 24 h
Result: Increased acetylated α-tubulin levels in a dose-dependent manner, indicating effective HDAC6 inhibition.
Did not significantly alter acetyl-histone H3 levels, indicating cellular selectivity toward HDAC6.
体内研究
(In Vivo)

SM-06-09 (Compound 3m) (25 mg/kg;腹腔注射;隔日一次,10-23 天) 在 C57BL/6 小鼠 SM1 黑色素瘤模型中显著抑制肿瘤生长并重编程肿瘤微环境,该处理显著降低肿瘤内 M2 型巨噬细胞比例。
SM-06-09 (25, 50, 100 mg/kg;口服灌胃;每日一次,2 周) 在 C57BL/6 小鼠 SM1 黑色素瘤模型中未观察到明显体重下降或器官毒性,提示具有良好的体内安全性与耐受性。
SM-06-09 (100 mg/kg;口服灌胃;每日一次,11-25 天) 联合 anti-PD-1 抗体 (10 mg/kg;腹腔注射;每周两次) 在 C57BL/6 小鼠 SM1 黑色素瘤模型中显著增强抗肿瘤效应并改善肿瘤免疫微环境。联合给药显著增加肿瘤内 CD45+ 免疫细胞与 F4/80+ 巨噬细胞浸润,提高 M1 型巨噬细胞比例及 M1/M2 比值,并增强 CD8+ T 细胞浸润,同时效应记忆与中央记忆 CD8+ T 细胞比例升高。

Animal Model: SM1 murine melanoma model (6-8 weeks, female, C57BL/6)
Dosage: 25 mg/kg
Administration: intraperitoneal iniections (i.p,), every other day for 10-23 days
Result: Reduced tumor growth significantly compared to the vehicle group.
Reduced the proportion of M2-like macrophages within tumors.
Animal Model: SM1 murine melanoma model (6-8 weeks, female, C57BL/6)
Dosage: 25, 50, 100 mg/kg
Administration: Oral gavage (p.o.), daily for 2 weeks
Result: Did not induce obvious body weight loss or observable organ toxicity.
Animal Model: SM1 murine melanoma model (6-8 weeks, female, C57BL/6; combined with 10 mg/kg anti-PD-1)
Dosage: 100 mg/kg
Administration: Oral gavage (p.o.), once daily for 11-25 days
Result: Produced significantly greater tumor growth inhibition than monotherapies.
Increased infiltration of CD45+ immune cells and F4/80+ macrophages in tumors.
Markedly elevated the percentage of M1-like macrophages and the M1/M2 ratio.
Enhanced CD8+ T cell infiltration with increased effector memory and central memory CD8+ T cells.

化学信息

分子量 367.32
分子式 C16H13N7O4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础